Aggressive antiplatelet therapy reduces the risk of coronary stent thrombosis associated with the GPIIb/IIIa PLA2 polymorphism

被引：0
|
作者：
Walter, DH [1 ]
Elsner, M [1 ]
Goette, S [1 ]
Auch-Schwelk, W [1 ]
机构：
[1] Univ Frankfurt, D-6000 Frankfurt, Germany
来源：
CIRCULATION | 1999年 / 100卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3744
引用
收藏
页码：709 / 710
页数：2
相关论文
共 40 条
  • [11] Perioperative antiplatelet therapy in patients at risk for coronary stent thrombosis undergoing noncardiac surgery
    Bigalke, Boris
    Seizer, Peter
    Geisler, Tobias
    Lindemann, Stephan
    Gawaz, Meinrad
    May, Andreas E.
    CLINICAL RESEARCH IN CARDIOLOGY, 2009, 98 (05) : 335 - 339
  • [12] Safety of only 2 weeks of ticlopidine therapy in patients at increased risk of coronary stent thrombosis: Results from the ATLAST (Antiplatelet therapy vs. antiplatelet therapy alone in patients at increased risk of stent thrombosis) trial
    Berger, PB
    Mahaffey, KW
    Buller, CE
    Deutsch, E
    Meler, SJ
    Batchelor, W
    Zidar, JP
    CIRCULATION, 1999, 100 (18) : 152 - 152
  • [13] Interaction between smoking and the glycoprotein IIIa PlA2 polymorphism in non-ST-elevation acute coronary syndromes
    Barakat, K
    Kennon, S
    Hitman, GA
    Aganna, E
    Price, CP
    Mills, PG
    Ranjadayalan, K
    North, B
    Clarke, H
    Timmis, AD
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 38 (06) : 1639 - 1643
  • [14] PlA1/PlA2 polymorphism does not influence response to Gp IIb-IIIa inhibitors in patients undergoing coronary angioplasty
    Verdoia, Monica
    Pergolini, Patrizia
    Camaro, Cyril
    Restifo, Maria
    Rolla, Roberta
    Schaffer, Alon
    Di Giovine, Gabriella
    Marino, Paolo
    Bellomo, Giorgio
    Suryapranata, Harry
    De Luca, Giuseppe
    BLOOD COAGULATION & FIBRINOLYSIS, 2013, 24 (04) : 411 - 418
  • [15] No evidence that the PLA1/PLA2 polymorphism of platelet glycoprotein IIIa is implicated in angiographically characterized coronary atherosclerosis and premature myocardial infarction
    Lagercrantz, J
    Bergman, M
    Lundman, P
    Tornvall, P
    Hjemdahl, P
    Hamsten, A
    Eriksson, P
    BLOOD COAGULATION & FIBRINOLYSIS, 2003, 14 (08) : 749 - 753
  • [16] Aspirin resistance is associated with platelet GP IIb/IIIa receptor polymorphism PLA2 and thrombotic events in coronary heart disease patients undergoing percutaneous coronary procedures
    Kiss, RG
    Kerecsen, G
    Bató, Z
    Melegh, B
    Császár, A
    Préda, I
    EUROPEAN HEART JOURNAL, 2000, 21 : 648 - 648
  • [17] The PlA1/A2 polymorphism of platelet glycoprotein IIIa is not associated with deep venous thrombosis
    Renner, W
    Winkler, M
    Hoffmann, C
    Köppel, H
    Seinost, G
    Brodmann, M
    Pilger, E
    INTERNATIONAL ANGIOLOGY, 2001, 20 (02) : 148 - 151
  • [18] Safety and efficacy of only 2 weeks of ticlopidine therapy in patients at increased risk of coronary stent thrombosis: Results from the Antiplatelet Therapy alone versus Lovenox plus Antiplatelet therapy in patients at increased risk of Stent Thrombosis (ATLAST) trial
    Berger, PB
    Mahaffey, KW
    Meier, SJ
    Buller, CE
    Batchelor, W
    Fry, ETA
    Zidar, JP
    AMERICAN HEART JOURNAL, 2002, 143 (05) : 841 - 846
  • [19] Platelet glycoprotein IIb/IIIa PlA2/PlA2 homozygosity associated with risk of ischemic cardiovascular disease and myocardial infarction in young men -: The Copenhagen City Heart Study
    Bojesen, SE
    Juul, K
    Schnohr, P
    Tybjærg-Hansen, A
    Nordestgaard, BG
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 42 (04) : 661 - 667
  • [20] EVALUATION OF PLATELET REACTIVITY DURING COMBINED ANTIPLATELET THERAPY IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE IN RELATION TO DIABETES TYPE 2 AND THE GPIIB/IIIA RECEPTOR GENE POLYMORPHISM
    Jastrzebska, M.
    Lisman, D.
    Szelepajlo, A.
    Oledzki, S.
    Chelstowski, K.
    Clark, J. S.
    Siennicka, A.
    JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2019, 70 (02): : 175 - 185
1234